Phase2 study of Glivec (imatinib mesylate, formerly known as STI571) in patients with relapsed o refractory sarcomas with c-kit or PDGFR [platelet derived growth factor receptors] expression.

Trial Profile

Phase2 study of Glivec (imatinib mesylate, formerly known as STI571) in patients with relapsed o refractory sarcomas with c-kit or PDGFR [platelet derived growth factor receptors] expression.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 May 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Sarcoma
  • Focus Therapeutic Use
  • Acronyms CST1571BJP04
  • Most Recent Events

    • 27 Mar 2012 Actual end date (Feb 2007) added as reported by University Hospital Medical Information Network - Japan.
    • 07 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top